CALLIDITAS THERAPEUTICS AB

CALLIDITAS THERAPEUTICS AB

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Calliditas Therapeutics AB_logo

Industry:
Company

Founded:
2004

Address:
Kungsbron 1, C8, Stockholm, Sweden Zipcode 111 22

Country:
Sweden

Phone:
46 84 11 30 05

Market Cap:
672.46M
Total Revenue:
874k
Total Assets:
1.51B
Total Cash:
996.3M

Subsidiary: Genkyotex


Key Executives
Name Title Pay Year Born
Ms. Renee Aguiar-Lucander Chief Exec. Officer N/A 1962(58 years old)
Mr. Fredrik Johansson Chief Financial Officer N/A 1977(43 years old)
Dr. Katayoun Welin-Berger Ph.D. VP of Operations N/A 1968(52 years old)
Dr. Johan Haggblad Chief Scientific Officer N/A 1958(62 years old)
Mr. Mikael Widell Head of Communications & IR N/A 1958(62 years old)
Mr. Jonathan A. Schur Group Gen. Counsel N/A N/A
Ms. Ann-Kristin Myde Head of Clinical Devel. & VP of Project Management N/A 1955(65 years old)
Mr. Andrew B. Udell B.Sc., M.B.A. Head of North America - Commercial N/A 1970(50 years old)
Dr. Krassimir Mitchev Head of Medical Affairs N/A 1959(61 years old)
Dr. Richard S. Philipson M.D. Chief Medical Officer N/A 1965(55 years old)



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state POSTPOST
According to Calliditas Therapeutics AB's financial reports the company's revenue in 2020 were 874k an increase(-99.53%) over the years 2019 revenue that were of 184.83M. In 2020 the company's total earnings were -433.49M while total earnings in 2019 were -32.58M( +1253.13%).
Company's stock symbol is CALT. Lastest price : 26.88. Total volume :14.99k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.calliditas.se

  • Host name: 46.253.203.109
  • IP address: 46.253.203.109
  • Location: Sweden
  • Latitude: 59.3247
  • Longitude: 18.056
  • Timezone: Europe/Stockholm

Loading ...
Loading ...


More informations about "Calliditas Therapeutics AB" on Search Engine

Calliditas Therapeutics AB

Calliditas.se Mar 8, 2021 Calliditas strengthens its US Commercial and Medical Affairs Organization Mar 4, 2021 Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice

Calliditas Therapeutics AB

Calliditas.se Offices – Calliditas Therapeutics AB. Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 …

Calliditas Therapeutics AB

Calliditas.se This is Calliditas – Calliditas Therapeutics AB

Calliditas Therapeutics AB

Calliditas.se Press releases – Calliditas Therapeutics AB

Calliditas Therapeutics AB

Calliditas.se Nefecon – Calliditas Therapeutics AB. Calliditas Therapeutics AB Kungsbron 1, C8 …

Calliditas Therapeutics AB

Calliditas.se Born 1956. Board member since 2009. Education: PhD in Genetics from the …

Calliditas Therapeutics AB

Calliditas.se Our Pipeline – Calliditas Therapeutics AB

Calliditas Therapeutics AB

Calliditas.se He also studies experimental therapeutics in an effort to find new treatments for glomerular …

Calliditas Therapeutics AB

Calliditas.se Media – Calliditas Therapeutics AB. Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 …

Calliditas Therapeutics AB

Calliditas.se Articles of Association of Calliditas Therapeutics AB. Reg. no. 556659-9766. …

Calliditas Therapeutics AB

Calliditas.se Vision and Strategy – Calliditas Therapeutics AB

This is Calliditas – Calliditas Therapeutics AB

Calliditas.se Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic …

Our Pipeline – Calliditas Therapeutics AB

Calliditas.se In addition, Calliditas have in-licensed Budenofalk 3 mg oral capsules and intend to develop Budenofalk in the United States for the treatment of AIH, subject to regulatory feedback. Calliditas plan to discuss the development plans with the FDA for AIH …

Calliditas Therapeutics AB (CALT) Company Profile & Facts

Finance.yahoo.com Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with...

Calliditas Therapeutics AB (CALT) Stock Price, News, Quote

Finance.yahoo.com Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA...

Management Team – Calliditas Therapeutics AB

Calliditas.se Jul 15, 2020 · Born 1962. CEO since 2017. Education: BA in Finance from Stockholm School of Economics.MBA from INSEAD. Experience: Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector.Before that, she served as a Partner in the venture capital …

Press releases – Calliditas Therapeutics AB

Calliditas.se Mar 15, 2021 · Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766

CALT Stock Price | Calliditas Therapeutics AB ADR Stock

Marketwatch.com Calliditas Therapeutics AB ADR Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product...

Board of Directors – Calliditas Therapeutics AB

Calliditas.se Born 1956. Board member since 2009. Education: PhD in Genetics from the University of Umeå.. Experience: Lennart Hansson has broad experience from leading positions within pharmaceutical development and business development in both biotech and pharma companies such as KabiGen AB, Symbicom AB, AstraZeneca, Biovitrum AB and as CEO of Arexis AB.Lennart was responsible for …

Nefecon – Calliditas Therapeutics AB

Calliditas.se Calliditas Therapeutics AB Kungsbron 1, C8 SE-111 22 Stockholm Sweden. Company number: 556659-9766

Calliditas Therapeutics AB to Host Earnings Call

Finance.yahoo.com NEW YORK, NY / ACCESSWIRE / February 18, 2021 / Calliditas Therapeutics AB (OTC PINK:CLTEF) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on ...

CALTX:Stockholm Stock Quote - Calliditas Therapeutics AB

Bloomberg.com About Calliditas Therapeutics AB Calliditas Therapeutics AB operates as a biotech company. The Company develops and discovers various types of novel treatments in orphan indications, with an ...

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large

Themarketsdaily.com Mar 15, 2021 · Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with...

Calliditas Therapeutics AB News - Investors Hub

Ih.advfn.com Jan 26, 2021 · Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in …

CALT - Calliditas Therapeutics AB • BioPharmCatalyst

Biopharmcatalyst.com STOCKHOLM, Feb. 4, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient has been dosed in the global open …

CALT | Calliditas Therapeutics AB ADR Profile | MarketWatch

Marketwatch.com Mar 23, 2021 · Calliditas Therapeutics AB ADR. Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of …

Calliditas Therapeutics AB | LinkedIn

Linkedin.com Calliditas Therapeutics AB 1,067 followers 3w Calliditas today announced that the first patient has been dosed in the global open-label extension (OLE) of the Phase 3 NefIgArd study.

Positive Phase 1 results in high-dose setanaxib trial

Ih.advfn.com STOCKHOLM, Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.. The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with ...

CALT:NASDAQ GS Stock Quote - Calliditas Therapeutics AB

Bloomberg.com Calliditas Therapeutics AB operates as a biotech company. The Company develops and discovers various types of novel treatments in orphan indications, with an initial focus on renal and hepatic ...

CLTEF | Calliditas Therapeutics AB Stock Price & News - WSJ

Wsj.com Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for...

CALLIDITAS THERAPEUTICS AB (CLTEF) Stock Price, News

Finance.yahoo.com Find the latest CALLIDITAS THERAPEUTICS AB (CLTEF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Calliditas strengthens its US Commercial and Medical

Ih.advfn.com STOCKHOLM, March 8, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced the appointment of three industry veterans: Warren Brooks, PhD, as Vice President of US Medical Affairs, Teona Johnson as Head of US Marketing and David Ferraro as Head of US Sales.. Calliditas Therapeutics has bolstered its US organization with three pharmaceutical veterans as it …

Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

Marketbeat.com Calliditas Therapeutics AB (publ) has received 55.00% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Calliditas Therapeutics AB (publ) and other stocks. Vote “Outperform” if you believe CALT will outperform the S&P 500 over the long term.

CALT Stock Quote of Calliditas Therapeutics Ab ADR

Investorplace.com Jan 29, 2021 · In trading on Monday, shares of Calliditas Therapeutics AB - American Depositary S (CALT) crossed below their 200 day moving average of $27.28, changing hands as low as $26.98 per share. Calliditas...

Calliditas Therapeutics AB News - Investors Hub

Ih.advfn.com Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an...

Calliditas Therapeutics AB - Company Profile - BCIQ

Bciq.biocentury.com Nov 10, 2020 · Also debuting on NASDAQ Friday was Calliditas Therapeutics AB.....million ADSs at $19.50, and 924,000 shares at SEK89.7 ($9.80) in a concurrent private placement. Calliditas.....U.S. (see “Genetron Looks to NASDAQ for China Expansion” ). Elizabeth S. Eaton, Staff Writer Pliant Therapeutics Inc. Calliditas Therapeutics AB Applied...

Calliditas Announces Submission of New Drug Application to

Ih.advfn.com STOCKHOLM, March 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN).

CALLIDITAS THERAPEUTICS AB

Calliditas.gcs-web.com Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product ... Calliditas Therapeutics AB ...

Calliditas Therapeutics AB, CALT:NSQ summary - FT.com

Markets.ft.com Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with in flammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule ...

CALT | Calliditas Therapeutics AB ADR Stock Price & News - WSJ

Wsj.com View the latest Calliditas Therapeutics AB ADR (CALT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Calliditas Therapeutics Seeks U.S. Capital Via IPO (NASDAQ)

Seekingalpha.com May 19, 2020 · Calliditas Therapeutics AB has filed to raise $75 million in an IPO of its ADSs representing common shares, according to an F-1 registration statement. The company is developing drug treatments ...

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short

Theenterpriseleader.com Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw a large decline in short interest in February. As of February 12th, there was short interest totalling 3,800 shares, a decline of 24.0% from the January 28th total of 5,000 shares. Based on an average daily volume of 23,500 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% […]

Calliditas Therapeutics AB American Depositary Shares

Nasdaq.com Calliditas Therapeutics AB American Depositary Shares (CALT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Calliditas Therapeutics AB Number of Employees 2020-2020

Macrotrends.net Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

Calliditas Therapeutics AB ROE 2020-2020 | CALT | MacroTrends

Macrotrends.net Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

CALT Calliditas Therapeutics AB (publ) Stock Quote

Finviz.com Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated ...

Calliditas Therapeutics AB - Stock Price History | CALT

Macrotrends.net Historical daily share price chart and data for Calliditas Therapeutics AB since 2021 adjusted for splits. The latest closing stock price for Calliditas Therapeutics AB as of March 31, 2021 is 27.57.. The all-time high Calliditas Therapeutics AB stock closing price was 36.65 on November 30, 2020.; The Calliditas Therapeutics AB 52-week high stock price is 38.00, which is 37.8% above the ...

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Coverage

Theenterpriseleader.com Mar 02, 2021 · HC Wainwright assumed coverage on shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in a report released on Friday, The Fly reports. The firm issued a buy rating and a $52.00 price objective on the stock. Separately, Zacks Investment Research raised Calliditas Therapeutics AB (publ) from a sell rating to a hold rating in a research report on Wednesday, …

Calliditas Therapeutics Ab Sponsored Adr - CALT - Stock

Zacks.com Apr 12, 2021 · Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet …

Calliditas Therapeutics AB CALTX (Sweden: Stockholm)

Wsj.com Detailed company description & address for Calliditas Therapeutics AB. Dow Jones, a News Corp company About WSJ News Corp is a network of leading companies in …

CALT | Calliditas Therapeutics AB ADR Company Profile

Wsj.com Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for ...

Calliditas Therapeutics AB Revenue 2020-2020 | CALT

Macrotrends.net Calliditas Therapeutics AB revenue from 2020 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which …

CALT Stock Price & Charts | Calliditas Therapeutics

Ycharts.com Description: Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications.

Calliditas Therapeutics AB Return on Investment 2020-2020

Macrotrends.net Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

CALT - Calliditas Therapeutics AB - American Depositary

Benzinga.com Jan 01, 2010 · Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease Vandana Singh Mon, 15 Mar 2021 06:45:46 -0400; Calliditas Announced Submission of NDA to FDA for Nefecon in Patients with ...

Calliditas Therapeutics AB Earnings Yield 2020-2020 | CALT

Macrotrends.net Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

CALLIDITAS THERAPEUTICS AB (PUBL) : CALTX Stock Price

Marketscreener.com Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA …